Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 19.5 mg intrauterine system for intrauterine use. It releases hormone locally to thicken cervical mucus, inhibit sperm motility and suppress endometrial growth, thereby preventing fertilization and implantation in women of reproductive age.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide with consistent quality and regulatory adherence.

Kyleena, a levonorgestrel‑releasing intrauterine system, is used within the contraceptive pathway to prevent pregnancy. - Contraception: provides long‑acting reversible birth control for up to five years. - Prevention of pregnancy: reduces the risk of unintended pregnancy in women of childbearing potential. - Family planning: supports planned childbearing by offering reliable, user‑independent contraception.

The intrauterine system may be associated with a range of adverse events, which are categorized by frequency and severity. Common Side Effects: - Irregular vaginal bleeding or spotting. - Amenorrhea (absence of periods). - Cramping or pelvic pain after insertion. - Breast tenderness. Serious or Rare Side Effects: - Uterine perforation during insertion. - Expulsion of the device. - Pelvic inflammatory disease. - Severe allergic reaction (anaphylaxis).

Before prescribing Kyleena, clinicians should observe several precautionary measures to ensure safety and effectiveness. - Confirm negative pregnancy test: verify the patient is not pregnant prior to insertion. - Evaluate uterine anatomy: assess for fibroids, septa or other abnormalities that may impede placement. - Treat active pelvic infection: resolve any current infection before device insertion. - Avoid in known levonorgestrel hypersensitivity: discontinue use if allergic reaction occurs. - Monitor bleeding patterns: advise follow‑up if bleeding becomes heavy or prolonged. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Kyleena can interact with other medicines that affect hormone metabolism or uterine environment. Major Interactions (Avoid): - Enzyme inducers (e.g., rifampicin, carbamazepine): may markedly reduce levonorgestrel levels and contraceptive efficacy. - Anticonvulsants (e.g., phenytoin, phenobarbital): can accelerate hormone clearance, increasing risk of unintended pregnancy. Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): limited evidence of reduced efficacy; monitor bleeding. - Antifungal agents (e.g., ketoconazole): may affect hormone metabolism; observe for changes. - Herbal supplements (e.g., St. John’s wort): can induce hepatic enzymes and lower hormone levels; counsel patient.